PubMed · 2000 · 309 citations · 127 references
MedicineHematologyNephrologyDialysisHemodialysisIron Metabolism DisordersAnemiaAnemia Management In HemodialysisAnemia Of Chronic DiseaseIron DeficiencyIron HomeostasisIron MetabolismBlood Loss AnemiaIntravenous Iron AdministrationIron Storage DisordersIron Therapy In DialysisIron-restricted ErythropoiesisOral Iron SupplementationReticulocyte IndicesSerum Ferritin Assessment
Recent knowledge gained regarding the relationship between erythropoietin, iron, and erythropoiesis in patients with blood loss anemia, with or without recombinant human erythropoietin therapy, has implications for patient management. Under conditions of significant blood loss, erythropoietin therapy, or both, iron-restricted erythropoiesis is evident, even in the presence of storage iron and iron oral supplementation. Intravenous iron therapy in renal dialysis patients undergoing erythropoietin therapy can produce hematologic responses with serum ferritin levels up to 400 microg/L, indicating that traditional biochemical markers of storage iron in patients with anemia caused by chronic disease are unhelpful in the assessment of iron status. Newer measurements of erythrocyte and reticulocyte indices using automated counters show promise in the evaluation of iron-restricted erythropoiesis. Assays for serum erythropoietin and the transferrin receptor are valuable tools for clinical research, but their roles in routine clinical practice remain undefined. The availability of safer intravenous iron preparations allows for carefully controlled studies of their value in patients undergoing erythropoietin therapy or experiencing blood loss, or both.
127
Anatole Besarab, W. Kline Bolton, Joan C. Egrie et al. · New England Journal of Medicine · 1998 · 1.9K citations · Full text
Iron-Chelating Therapy and the Treatment of Thalassemia
Nancy F. Olivieri, Gary M. Brittenham · Blood · 1997 · 1.1K citations · Full text